NCT00623649View on ClinicalTrials.gov

Safety,Tolerability and Pharmacokinetics of Multiple Ascending Doses of VCH 916 in Subjects With Chronic Hep C Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
HCV Infection
Interventions
DRUG

VCH 916

Dose escalation study with a full review of all safety data following each cohort.

DRUG

Placebo

Dose escalation study with a full review of all safety data following each cohort.

Trial Locations (5)

75208

The Liver INstitute at Methodist Dallas, Dallas

78215

Alamo Medical Research, San Antonio

K1H 8L6

Ottawa Hospital - General Campus, Ottawa

H3A 1A1

Royal Victoria Hospital, Montreal

00909

Fundacion de Investigacion de Diego, Santurce

Sponsors
All Listed Sponsors
collaborator

ViroChem Pharma

INDUSTRY

collaborator

Duke Clinical Research Institute

OTHER

lead

Vertex Pharmaceuticals Incorporated

INDUSTRY